Drugs / ALE1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07179640 | Sep 2025 → Jan 2027 expected | hypophosphatasia | Alesta Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-06 | Alesta Therapeutics | Results Alesta to Highlight ALE1 Clinical Progress at 44th Annual JP Morgan Healthcare Conference alestatherapeutics.com ↗
Initial data from our ALE1 healthy volunteer study demonstrate a favorable safety profile, reinforcing our confidence as we move into patient studies. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-18 | BioMarin Pharmaceutical | BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin’s Pipeline biomarin.com ↗ |
| 2026-01-06 | Alesta Therapeutics | Alesta to Highlight ALE1 Clinical Progress at 44th Annual JP Morgan Healthcare Conference alestatherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALE1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07179640 ↗ |
| Route | Oral | “Orally Administered ALE1” NCT07179640 ↗ |